IMPACC-MEDVAMC

该补充提案的目的是了解气道疾病的原因，从而改善 这些常见且使人衰弱的疾病的诊断和治疗。免疫表型分析 COVID-19 队列 (IMPACC) 研究中的评估协调了一个全国性多机构联盟， 从住院的 COVID-19 感染者那里收集详细的临床数据和生物样本， 识别与临床疾病过程相关的免疫特征/分子生物标志物的目标，以允许 临床干预和决策的优先顺序。该补充品支持贝勒学院 Medicine 和 Michael E. DeBakey VA 医疗中心 (MEDVAMC) 参与 IMPACC，以促进 COVID-19 住院患者的筛查和登记。拟议的补充研究范围 家长资助 R01 AI135803，中度至重度哮喘的真菌发病机制。这个补充是 出于临床数据和样本收集/处理的目的而提交，范围仅限于 确诊患有 COVID-19 的患者。根据 MEDVAMC 中 COVID-19 疾病的预测趋势，我们 估计 6 个月内最多可招募 50 名 COVID-19 患者。由于登记者将被跟踪 至一年，预算延长至18个月。收集的数据将包括主要数据和次要数据 临床和机械终点以及探索性临床和机械终点。

The objective of this supplement proposal is to understand the causes of airway diseases and thereby improve diagnosis and therapy of these common and debilitating of human ailments. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical interventions and decision making. This supplement supports Baylor College of Medicine's and the Michael E. DeBakey VA Medical Center's (MEDVAMC) participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent grant R01 AI135803, Fungal Pathogenesis of Moderate to Severe Asthma. This supplement is submitted for the purpose of Clinical data and sample collection/processing and the scope will be confined to patients confirmed to have COVID-19. Based on projected trends in COVID-19 disease in MEDVAMC, we estimate that up to 50 COVID-19 patients can be enrolled within 6 months. As enrollees will be followed for up to one year, the budget extends to 18 months. Data to be collected will consist of both primary and secondary clinical and mechanistic endpoints as well as exploratory clinical and mechanistic endpoints.